Artios Pharma Ltd.

http://www.artiospharma.com

Artios is a leading independent DNA Damage Response (DDR) company focussed on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. About DNA Damage Response (DDR) DNA Damage occurs in cells throughout the body every day. To counteract the harmful effects that DNA damage can cause, the human body possesses a network of DNA repair pathways, which act to correct the damage. This process is known as the DNA Damage Response (DDR). Defects in the body’s DDR can lead to an increased risk of cancer. Human cells have multiple DNA repair pathways, but in cancer cells, some of these pathways are lost, which result in genetic instability. Changes to DNA repair pathways can also drive the growth of tumours. By inhibiting DDR in cancer cells that have impaired repair pathways, scientists can selectively kill cancerous cells. DDR inhibitors, therefore, have the potential to act as: single agents that selectively kill tumour cells through synthetic lethality; adjunctive therapy to overcome resistance to current cytotoxics, and potentiating agents to radiotherapy and novel therapies including immune-oncology treatments. *

	Start	2016-05-01 established
	Industry	DNA Damage Response (DDR) cancer therapy
	Industry 2	drug development
	Person	Martin, Niall (Artios Pharma 201808 CEO before Mission Therapeutics + Kudos Pharmaceuticals)
	Person 2	Staples, Nick (Artios Pharma 201609 CBO)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Babraham Hall (B301)
	City	CB22 3AT Cambridge, Cambridgeshire
	Tel	+44-1223-804180
		Address record changed: 2016-09-26

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Artios Pharma Ltd.. (9/21/16). "Press Release: Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies". Cambridge.

		Record changed: 2018-08-14

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Artios Pharma Ltd.

More documents for Artios Pharma Ltd.